Thermo Fisher Scientific (TMO)
The desk's stance
On our research list, not on the slate.
What the company does
The picks and shovels of drug development: lab instruments, bioprocessing, and contract manufacturing for the whole industry — whoever wins the drug wars, the tools bill gets paid.
In short: Analytical instruments and biopharma services. Category: Life Sciences Tools & CDMO. Sector: Healthcare, Diagnostics & Research.
G-Street Value and Score
G-Street Value: $631.08, computed Oct 18, 2026 (confidence: high).
How we got there: 70% analyst leg $687.42 (5 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $499.62 (18.11× fwd EPS anchored to healthcare multiples).
G-Street Score: 53 out of 100 (Weak).
- Top-line growth & guidance: 10 of 32
- Margin power: 4 of 15
- Revenue visibility & quality: 11 of 11
- Profitability & balance sheet: 18 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 5 of 12
Our current thesis
Updated Oct 18, 2026
The thesis
- Biopharma 'picks and shovels' leader with 84% recurring revenue across consumables and services.
- Four straight beat-and-raise quarters confirm accelerating bioprocessing orders and demand inflection.
- Clario acquisition expands high-margin clinical trial services, supporting a $29.7B backlog.
Risks
- Heavy $42.5B debt load requires substantial cash flow allocation toward post-M&A deleveraging.
- Trading at 25.0x forward earnings near 52-week highs leaves zero valuation cushion.
- Academic and government end-market budget constraints could dampen analytical instrument demand.
What we're watching
- Q3 2026 earnings release on October 21 for bioprocessing order velocity and guidance.
- Debt paydown cadence toward targets following the $9.1B Clario acquisition integration.
- Recovery in China instrument spending and customer laboratory capital expenditure budgets.
Latest
TMO trades at $690.00, up 31.1% over three months and hovering just below 52-week highs of $704.00. Q2 2026 revenue grew 10.5% year-over-year to $11.99B, marking a fourth straight beat-and-raise quarter on re-accelerating bioprocessing demand. At 25.0x forward earnings and matching consensus price targets ($690.62), the multiple leaves little valuation cushion ahead of Q3 earnings.
Key numbers
As of Oct 16, 2026: market cap $255.1B · revenue growth +10.5% year over year · gross margin 41.0% · net margin 15.0% · forward P/E 25.0 · next earnings Oct 21, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- Morgan Stanley, Overweight: $730 target (October 2026). Source: tickernerd.com
- Barclays, Overweight: $750 target (October 2026). Source: tickernerd.com
- Guggenheim, Buy: $740 target (October 2026). Source: investing.com
- UBS, Buy: $730 target (September 2026). Source: investing.com
- Goldman Sachs, Buy: $780 target (September 2026). Source: perplexity.ai
On the Gainz Lab maps
Who it does business with
- Thermo Fisher Scientific supplies Eli Lilly — Bioprocessing & tools. The instruments, consumables, and bioprocessing capacity under every blockbuster pipeline on this map.